CALC · Calcimedica, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $15.23M | $14.48M | $15.86M | $14.11M | $18.90M | $20.96M |
| SG&A | $7.89M | $9.73M | $22.22M | $19.10M | $17.04M | $8.87M |
| Total Operating Expenses | $23.12M | $24.20M | $38.08M | $36.18M | $35.95M | $29.83M |
| D&A | $46.0K | $58.0K | $52.0K | $338.0K | $519.0K | $395.0K |
| Operating Income | ($23.12M) | ($24.20M) | ($38.08M) | ($36.18M) | ($35.95M) | ($29.83M) |
| Interest Expense | $0 | - | - | - | - | - |
| Income Tax | $0 | $0 | $1.0K | - | - | - |
| Net Income | ($29.56M) | ($13.70M) | ($34.36M) | ($35.60M) | ($35.82M) | ($27.53M) |
| EPS - Basic | ($1.97) | ($1.22) | ($7.66) | ($1.69) | - | - |
| EPS - Diluted | ($1.97) | ($1.22) | ($7.66) | ($1.69) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.52M | $7.93M | $5.53M | $17.30M | $13.36M | $33.42M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.16M | $2.00M | $1.42M | $1.72M | $527.0K | $2.51M |
| Current Assets | $13.53M | $19.66M | $11.61M | $39.67M | $67.08M | $99.24M |
| Total Assets | $13.59M | $19.79M | $12.19M | $39.67M | $69.09M | $101.79M |
| Current Liabilities | $3.78M | $3.68M | $4.03M | $3.70M | $4.06M | $7.00M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $20.23M | $5.38M | $4.03M | $3.70M | $4.07M | $7.01M |
| Stockholders' Equity | ($6.64M) | $14.41M | $8.16M | $35.97M | $65.02M | $94.79M |
| Retained Earnings | ($189.33M) | ($159.76M) | ($146.06M) | ($204.79M) | ($169.19M) | ($133.37M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($21.18M) | ($21.15M) | ($25.73M) | ($22.88M) | ($31.50M) | ($32.06M) |
| Investing Cash Flow | $9.55M | ($4.42M) | $8.88M | $26.96M | $10.75M | ($42.56M) |
| Financing Cash Flow | $15.21M | $27.97M | $20.90M | ($139.0K) | $695.0K | $92.17M |
| CapEx | $28.0K | $8.0K | $78.0K | $308.0K | $488.0K | $1.02M |
| Free Cash Flow | ($21.21M) | ($21.15M) | ($25.81M) | ($23.19M) | ($31.99M) | ($33.09M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.72 | 1.54 | 0.75 | 0.65 | 0.89 | 1.20 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -217.5% | -69.2% | -282.0% | -89.8% | -51.8% | -27.0% |
| Return on equity | 445.1% | -95.1% | -421.2% | -99.0% | -55.1% | -29.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.58 | 5.34 | 2.88 | 10.72 | 16.53 | 14.18 |
| Quick ratio | 3.58 | 5.34 | 2.88 | 10.72 | 16.53 | 14.18 |
| Cash ratio | 3.05 | 2.15 | 1.37 | 4.68 | 3.29 | 4.78 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -2.05 | 1.37 | 1.49 | 1.10 | 1.06 | 1.07 |
| Liabilities / Assets | 1.49 | 0.27 | 0.33 | 0.09 | 0.06 | 0.07 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | 2.8x | 1.6x | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 4.5% | 36.4% | -5.2% | -0.6% | -20.5% | - |
| Net income growth (YoY) | -115.8% | 60.1% | 3.5% | 0.6% | -30.1% | - |
| EPS growth (YoY) | -61.5% | 84.1% | -353.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -0.2% | 18.0% | -11.3% | 27.5% | 3.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | 76.7% | -77.3% | -44.7% | -31.4% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CalciMedica against the 5 most active filers in the same SIC group.